Sarepta Therapeutics, Inc. (SRPT)
$
18.34
+0.27 (1.47%)
Key metrics
Financial statements
Free cash flow per share
-4.5053
Market cap
1.8 Billion
Price to sales ratio
0.7190
Debt to equity
0.9974
Current ratio
2.8882
Income quality
5.1893
Average inventory
967.7 Million
ROE
-0.0442
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for rare diseases. The diluted EPS is $2.34 accounting for potential share dilution. The financial data pertains to the fiscal year 2024 reflecting the overall performance of the company. The income before tax ratio is 0.14 which showcases the pre-tax margin and operational efficiency of Sarepta. Furthermore, the cost of revenue for the company is $319,099,000.00 highlighting its production and operational expenses. Despite these costs, the company earned an interest income of $71,767,000.00 showcasing its financial investments and ability to generate additional revenue streams. Sarepta offers the EXONDYS 51 injection and VYONDYS 53 for the treatment of Duchenne muscular dystrophy in patients with specific confirmed mutations in the dystrophin gene. The company is also progressing in developing AMONDYS 45, SRP-5051, SRP-9001, and SRP-9003, thereby solidifying its commitment to addressing rare genetic diseases through innovative therapies. Currently, the stock is reasonably priced at $19.23 appealing to a broad range of investors. This attractiveness is further supported by an average trading volume of 12,285,553.00 indicating moderate liquidity for potential and existing shareholders. With a mid-range market capitalization of $1,792,063,756.00 the company is a steady performer in its sector. It is a key player in the biotechnology industry, contributing significantly to the overall market landscape, while also driving innovation and growth in the healthcare sector. Through its collaborations with multiple organizations, Sarepta continues to enhance its research and development capabilities, positioning itself as a leader in genetic therapies and a vital contributor to advancements aimed at treating rare diseases.
Is Sarepta Therapeutics, Inc. (SRPT) a good investment?
Investing in Sarepta Therapeutics, Inc. (SRPT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Sarepta Therapeutics, Inc. (SRPT)'s stock forecast?
Analysts predict Sarepta Therapeutics, Inc. stock to fluctuate between $10.42 (low) and $138.81 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Sarepta Therapeutics, Inc.'s market capitalization?
As of 2025-08-29, Sarepta Therapeutics, Inc.'s market cap is $1,792,063,756, based on 97,713,400 outstanding shares.
How does Sarepta Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Sarepta Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Sarepta Therapeutics, Inc. (SRPT) stock?
To buy Sarepta Therapeutics, Inc. (SRPT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SRPT. Place an order (Market, Limit, etc.).
What is the best time to invest in Sarepta Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Sarepta Therapeutics, Inc. stock ever split?
Sarepta Therapeutics, Inc.'s last stock split was 1:6 on 2012-07-12.
How did Sarepta Therapeutics, Inc. perform in the last earnings report?
Revenue: $1,901,979,000 | EPS: $2.34 | Growth: -140.34%.
Where can I find Sarepta Therapeutics, Inc.'s investor relations reports?
Visit https://www.sarepta.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Sarepta Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Sarepta Therapeutics, Inc. stock?
All-time high: $173.25 (2024-06-21) | All-time low: $10.42 (2025-07-24).
What are the key trends affecting Sarepta Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
NEW YORK , Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE: ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (XNYS: BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions.
globenewswire.com
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
globenewswire.com
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sarepta (SRPT) To Contact Him Directly To Discuss Their Options
globenewswire.com
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
prnewswire.com
NEW YORK , Aug. 25, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
prnewswire.com
LOS ANGELES , Aug. 25, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the federal securities laws. Shareholders who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.
prnewswire.com
LOS ANGELES , Aug. 25, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.
globenewswire.com
NEW YORK, Aug. 24, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRPT) and certain of its officers.
globenewswire.com
SAN FRANCISCO, Aug. 23, 2025 (GLOBE NEWSWIRE) -- A securities class-action lawsuit is underway against Sarepta Therapeutics (NASDAQ: SRPT), triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit alleges that Sarepta misled investors by presenting ELEVIDYS as a safe and effective treatment with a clear path to broader regulatory approval.
globenewswire.com
Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.
See all news
